Emactuzumab has received fast track designation from the U.S. FDA for patients with tenosynovial giant cell tumors and who would not benefit from surgery. Treatment with emactuzumab has received fast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback